365 related articles for article (PubMed ID: 36140729)
21. Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome.
Ochi T; Fujiwara T; Ono K; Suzuki C; Nikaido M; Inoue D; Kato H; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Nakamura Y; Harigae H
Sci Rep; 2022 Aug; 12(1):14562. PubMed ID: 36028755
[TBL] [Abstract][Full Text] [Related]
22. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome.
Cuijpers ML; Raymakers RA; Mackenzie MA; de Witte TJ; Swinkels DW
Br J Haematol; 2010 May; 149(3):322-33. PubMed ID: 20067561
[TBL] [Abstract][Full Text] [Related]
24. Generation and Molecular Characterization of Human Ring Sideroblasts: a Key Role of Ferrous Iron in Terminal Erythroid Differentiation and Ring Sideroblast Formation.
Saito K; Fujiwara T; Hatta S; Morita M; Ono K; Suzuki C; Fukuhara N; Onishi Y; Nakamura Y; Kawamata S; Shimizu R; Yamamoto M; Harigae H
Mol Cell Biol; 2019 Apr; 39(7):. PubMed ID: 30670569
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract][Full Text] [Related]
26. When Ring Sideroblasts on Bone Marrow Smears Are Inconsistent with the Diagnosis of Myelodysplastic Neoplasms.
Girard S; Genevieve F; Rault E; Fenneteau O; Lesesve JF
Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885655
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.
Cazzola M; Malcovati L
Hematology Am Soc Hematol Educ Program; 2015; 2015():19-25. PubMed ID: 26637696
[TBL] [Abstract][Full Text] [Related]
28. Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia.
Furuyama K; Kaneko K
Int J Hematol; 2018 Jan; 107(1):44-54. PubMed ID: 29139060
[TBL] [Abstract][Full Text] [Related]
29. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
Yoshimi A; Abdel-Wahab O
Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
[TBL] [Abstract][Full Text] [Related]
30. Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options.
Abu-Zeinah G; DeSancho MT
J Blood Med; 2020; 11():305-318. PubMed ID: 33061728
[TBL] [Abstract][Full Text] [Related]
31. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Patnaik MM; Tefferi A
Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
[TBL] [Abstract][Full Text] [Related]
32. [Sideroblastic anemia].
Fujiwara T
Rinsho Ketsueki; 2019; 60(5):408-416. PubMed ID: 31168006
[TBL] [Abstract][Full Text] [Related]
33. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
Visconte V; Rogers HJ; Singh J; Barnard J; Bupathi M; Traina F; McMahon J; Makishima H; Szpurka H; Jankowska A; Jerez A; Sekeres MA; Saunthararajah Y; Advani AS; Copelan E; Koseki H; Isono K; Padgett RA; Osman S; Koide K; O'Keefe C; Maciejewski JP; Tiu RV
Blood; 2012 Oct; 120(16):3173-86. PubMed ID: 22826563
[TBL] [Abstract][Full Text] [Related]
34. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment.
Camaschella C
Semin Hematol; 2009 Oct; 46(4):371-7. PubMed ID: 19786205
[TBL] [Abstract][Full Text] [Related]
35. Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia.
Fujiwara T; Harigae H
Free Radic Biol Med; 2019 Mar; 133():179-185. PubMed ID: 30098397
[TBL] [Abstract][Full Text] [Related]
36. MDS/MPN-RS-T justified inclusion as a unique disease entity?
Montalban-Bravo G; Garcia-Manero G
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101147. PubMed ID: 32460979
[TBL] [Abstract][Full Text] [Related]
37. Pathophysiology and genetic mutations in congenital sideroblastic anemia.
Fujiwara T; Harigae H
Pediatr Int; 2013 Dec; 55(6):675-9. PubMed ID: 24003969
[TBL] [Abstract][Full Text] [Related]
38. Establishment of a cell model of X-linked sideroblastic anemia using genome editing.
Kaneko K; Kubota Y; Nomura K; Hayashimoto H; Chida T; Yoshino N; Wayama M; Ogasawara K; Nakamura Y; Tooyama I; Furuyama K
Exp Hematol; 2018 Sep; 65():57-68.e2. PubMed ID: 29908199
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution.
Hayama K; Abe Y; Kamata H; Okina S; Murakami Y; Kanoh Y; Suzuki T
Int J Hematol; 2022 Apr; 115(4):508-514. PubMed ID: 35064465
[TBL] [Abstract][Full Text] [Related]
40. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
